Stem Cell Transplant Outperforms Drug Therapy for Younger Middle-Aged Aplastic Anemia Patients

Severe aplastic anemia is one of the most unforgiving diagnoses in hematology. The bone marrow, the factory that manufactures red blood cells, white blood cells, and platelets, simply stops working, leaving patients vulnerable to profound anemia, life-threatening infections, and spontaneous bleeding. For decades, the standard first-line treatment for patients over the age of forty has been immunosuppressive therapy, often paired in recent years with the thrombopoietin receptor agonist eltrombopag, a drug that stimulates platelet production. Now, a large multicenter retrospective study published in the Annals of Hematology suggests that for a specific age band within this population, a more aggressive strategy may deliver meaningfully better outcomes: upfront transplantation of stem cells from a partially matched family donor.

The research, conducted by a team led by Xiaohui Xiao, Guiping Chen, and Cong Xu across multiple Chinese hematology centers, compared two first-line strategies in 123 newly diagnosed patients with severe aplastic anemia aged between 40 and 65, treated between 2016 and 2024. Sixty-seven patients underwent haploidentical hematopoietic stem cell transplantation, a procedure in which the donor is a family member, typically a parent or child, who shares only one matched human leukocyte antigen haplotype with the recipient. The remaining 56 patients received the preferred conventional regimen: immunosuppressive therapy combined with eltrombopag, a combination that has become the default first-line option for older adults precisely because it avoids the risks of transplantation in a population less able to tolerate intensive procedures.

The logic of the comparison is rooted in a long-standing clinical dilemma. Immunosuppressive therapy, usually built around horse antithymocyte globulin and cyclosporine, works by damping down the aberrant immune destruction of hematopoietic stem and progenitor cells that drives the disease. Eltrombopag was added to this regimen after trials showed it could boost response rates and improve blood counts. But the combination is far from curative. A substantial fraction of patients never respond, others relapse, and some evolve to clonal complications such as myelodysplastic syndrome. Transplantation, by contrast, replaces the failed marrow entirely with healthy donor stem cells, offering the possibility of a durable cure, but at the cost of transplant-related mortality, graft-versus-host disease, and infections during the period of immune reconstitution. For younger patients with a fully matched sibling donor, transplantation has long been the favored first option. The open question has been whether the same logic applies to middle-aged and older patients when only a half-matched family donor is available.

The study’s findings on response rates were striking. At three months after treatment, 17.9 percent of the transplant group had achieved a complete response, meaning fully normalized blood counts, compared with just 5.4 percent of those on immunosuppressive therapy plus eltrombopag. By six months, the gap had widened: 44.8 percent versus 17.9 percent. At twelve months, 64.2 percent of transplant recipients had achieved complete response compared with 33.9 percent of the drug-treated group, differences that were all statistically significant. In a disease where the depth and durability of blood count recovery correlate closely with quality of life and survival, these numbers represent a substantive clinical signal, not a marginal one.

Survival outcomes told a more nuanced story. Three-year overall survival was remarkably similar between the two groups, at 78.0 percent for the transplant arm and 80.3 percent for the immunosuppressive therapy plus eltrombopag arm, a difference that did not reach statistical significance. The researchers also performed a landmark analysis restricted to patients who had survived their first six months of treatment, a statistical technique designed to correct for the tendency of early transplant mortality to bias survival comparisons. Conditioned on surviving to that checkpoint, three-year overall survival was again comparable: 92.2 percent for transplant recipients versus 88.9 percent for the drug group. In other words, although transplantation produced deeper and faster hematologic recovery, it did not translate into a survival advantage across the entire 40-to-65 age range during the study’s follow-up window.

The most clinically provocative result emerged when the investigators stratified patients by age. Among those aged 40 to 49, three-year failure-free survival, a measure that captures both treatment failure and relapse, was significantly higher after transplantation: 82.9 percent versus 60.1 percent with drugs, a statistically significant difference. For patients aged 50 to 65, however, there was essentially no difference between the strategies, with the comparison yielding a P value of 0.984. This age-dependent divergence suggests that the durability advantage of a donor-derived immune system may only outweigh the upfront hazards of transplantation in patients whose physiological reserve and life expectancy are sufficient for those late benefits to materialize before competing risks intervene.

The technical significance of this study lies partly in its scale and design. Retrospective comparisons are inherently vulnerable to selection bias, since clinicians and patients choose treatments based on factors such as donor availability, comorbidities, and disease severity that can independently influence outcomes. By pooling patients across multiple centers and analyzing a relatively homogeneous age window, the researchers aimed to reduce some of that confounding, though the authors and independent commentators alike would acknowledge that only a prospective randomized trial can definitively settle the question. The study also benefited from independent verification of its survival analyses, an unusual methodological safeguard that strengthens confidence in the reported statistics.

For the field of haploidentical transplantation, the findings arrive at a moment of rapid evolution. Half-matched transplants were once considered a last resort because of high rates of graft rejection and graft-versus-host disease. Improvements in graft engineering, post-transplant cyclophosphamide prophylaxis, and supportive care have progressively narrowed the gap between haploidentical and fully matched transplantation. The current study, spanning cases from 2016 to 2024, reflects that modern era, and its results give weight to the argument that a readily available family donor should not be discounted simply because the patient has passed the conventional age threshold for upfront transplantation.

Clinically, the study does not demand an immediate rewrite of treatment guidelines, but it does complicate the conversation that hematologists have with newly diagnosed middle-aged patients. The current standard of care, immunosuppressive therapy with eltrombopag, remains a reasonable first choice that spares many patients the risks of a transplant, and overall survival in this cohort was excellent with both strategies. But the data indicate that patients in their forties who have a suitable half-matched family donor may achieve more durable, treatment-free blood count recovery by proceeding to transplantation upfront, rather than waiting for the drug regimen to fail and then transplanting in a compromised state. For patients in their fifties and early sixties, the calculus appears more balanced, and the lower-intensity medical route may be preferable.

The study was funded in part by China’s National Key Research and Development Program and the National Natural Science Foundation of China, and the authors declared no conflicts of interest. Its publication as an open-access article means that clinicians worldwide, including in regions where fully matched donors are scarce and haploidentical transplantation carries the greatest practical weight, can examine the full dataset. As follow-up extends and prospective trials are designed, the central lesson of this work is likely to endure: age alone is an incomplete guide to treatment selection in severe aplastic anemia, and the decade between forty and fifty may mark a genuine biological tipping point in the trade-off between the slow, uncertain path of immune re-education and the swift, definitive, but riskier replacement of the marrow itself.

Subject of Research: First-line treatment of severe aplastic anemia in patients aged 40–65 comparing haploidentical stem cell transplantation with immunosuppressive therapy plus eltrombopag

Article Title: Haploidentical hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for severe aplastic anemia patients aged 40–65: a multicenter retrospective study

Article References: Xiao, X., Chen, G., Xu, C., Wu, L., Liu, X., Zhou, M., Chen, X., Zhou, R., Mo, W., Li, Y., Xu, S., Zhang, Y., Lin, D., & Wang, S. (2026). Haploidentical hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for severe aplastic anemia patients aged 40–65: a multicenter retrospective study. Annals of Hematology. https://doi.org/10.1007/s00277-026-07289-2

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07289-2

Keywords: severe aplastic anemia, haploidentical transplantation, hematopoietic stem cells, immunosuppressive therapy, eltrombopag, bone marrow, failure-free survival, overall survival, hematology, first-line treatment, graft-versus-host disease, retrospective study